BioNTech Signs Rare Disease Co-Development Deal With Genevant & Licenses LNP Platform

BioNTech AG, Europe’s largest privately held biotech, has signed two deals with Genevant Sciences Ltd., a joint venture created earlier this year by Vancouver-based Arbutus Biopharma Corp. and Roivant Sciences GMBH, which are expected to support the clinical ambitions of both companies.

In the first deal, the companies have agreed to combine Genevant’s lipid nanoparticle (LNP) drug delivery technology with BioNTech’s mRNA drug discovery platform in a 50/50 co-development and co-commercialization covering five undisclosed rare disease programs